普拉克索联合多巴丝肼治疗帕金森病的有效性及对活化T细胞趋化因子、α-突触核蛋白的影响  

Efficacy of pramipexole combined with dopamine in the treatment of Parkinson's disease and its effects on activated T cell chemokines and α-synuclein

作　　者：陈金刚 彭俊祥 杨亚运 CHEN Jingang;PENG Junxiang;YANG Yayun(Department of Internal Medicine,Luoyang Oriental People's Hospital—the Third Affiliated Hospital of Henan University of Science and Technology,Luoyang 417003,Henan,China)

机构地区：[1]河南科技大学第三附属医院暨洛阳市东方人民医院内科,河南洛阳417003

出　　处：《右江医学》2024年第7期641-646,共6页Chinese Youjiang Medical Journal

摘　　要：目的探讨普拉克索片联合多巴丝肼片治疗帕金森病(PD)的有效性及对活化T细胞趋化因子(RANTES)、α-突触核蛋白(α-syn)的影响。方法以2019年4月至2021年9月洛阳市东方人民医院收治的84例PD患者为研究对象,采用随机数字表将患者分为对照组和联合组,各42例。对照组给予多巴丝肼片治疗,联合组在此基础上给予普拉克索片治疗。比较两组临床疗效及治疗前、治疗1个月、治疗3个月后帕金森病综合评分量表(UPDRS)、蒙特利尔认知评估量表(MoCA)、日常生活能力量表(ADL)、P300(潜伏期、波幅)、疾病相关指标[白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)、RANTES、α-syn]、不良反应。结果联合组临床总有效率为95.24%,高于对照组的78.58%(P<0.05);与对照组相比,治疗1个月、3个月后联合组UPDRS评分明显降低,MoCA、ADL评分明显升高(P<0.05);与治疗前相比,治疗1个月、3个月后两组P300潜伏期明显缩短,波幅明显升高,其中联合组改变更为显著(P<0.05);与治疗前相比,治疗1个月、3个月后两组血清IL-6、IL-1β、RANTES、α-syn水平均呈持续下降趋势,其中联合组下降更为显著(P<0.05);联合组不良反应发生率为11.90%,与对照组的7.14%相比,差异无统计学意义(P>0.05)。结论多巴丝肼片联合普拉克索片治疗PD疗效确切,能有效改善患者神经功能和认知功能,减轻炎症反应,提高生活质量,安全可靠,其机制可能与调控RANTES、α-syn表达有关。Objective To explore the effectiveness of pramipexole tablets combined with dopazazine tablets in the treatment of Parkinson's disease(PD)and its effects on activated T cell chemokines(RANTES)andα-synuclein(α-syn).Methods A total of 84 patients with PD admitted to Luoyang Oriental People's Hospital from April 2019 to September 2021 were selected as research objects.They were divided into control group and combination group by random number table,with 42 cases in each group.The control group were given dopamazide tablets,and the combination group were given pramexol tablets on this basis.And then,clinical efficacy as well as the Comprehensive Parkinson's Disease Scale(UPDRS),Montreal Cognitive Assessment(MoCA)Scale,Activity of Daily Living(ADL)Scale,P300(latency,amplitude),disease-related indicators(interleukin-6[IL-6],interleukin-1β[IL-1β],RANTES,α-syn)before treatment,at 1 month and 3 months after treatment,and adverse reactions of the two groups were compared.Results The total effective rate of the combination group was 95.24%,which was higher than that of the control group(78.58%)(P<0.05).Compared with the control group,after 1 month and 3 months of treatment,the UPDRS scores of the combination group were significantly decreased,while the MoCA and ADL scores were significantly increased(P<0.05).Compared with those before treatment,the P300 latency of the two groups was significantly shortened,and the amplitude of the wave was significantly increased after 1 month and 3 months of treatment,and change in the combination group was even more significant(P<0.05).Compared with those before treatment,serum levels of IL-6,IL-1β,RANTES andα-syn in the two groups were decreased continuously after 1 month and 3 months of treatment,especially in the combination group(P<0.05).The incidence of adverse reactions in the combination group was 11.90%,compared with 7.14%in the control group,the difference was not statistically significant(P>0.05).Conclusion Dopamazid tablets combined with pramexol tablets are effective in

关 键 词：多巴丝肼片 普拉克索片 帕金森病 神经功能 认知功能 P300 

分 类 号：R742.5[医药卫生—神经病学与精神病学]